Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.46 USD
+0.09 (3.80%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $2.48 +0.02 (0.81%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Innate Pharma SA Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 67 | 61 | 29 | 80 | 96 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 67 | 61 | 29 | 80 | 96 |
Selling & Adminstrative & Depr. & Amort Expenses | 80 | 121 | 86 | 151 | 126 |
Income After Depreciation & Amortization | -14 | -61 | -57 | -71 | -30 |
Non-Operating Income | 8 | 5 | 8 | 6 | 13 |
Interest Expense | 2 | 6 | 5 | 8 | 6 |
Pretax Income | -8 | -61 | -54 | -73 | -23 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -61 | -54 | -73 | -23 |
Extras & Discontinued Operations | 0 | 0 | -9 | 0 | 0 |
Net Income (GAAP) | -8 | -61 | -62 | -73 | -23 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -13 | -51 | -6 | -12 |
Depreciation & Amortization (Cash Flow) | 6 | 48 | 5 | 65 | 19 |
Income After Depreciation & Amortization | -14 | -61 | -57 | -71 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 84.11 | 79.59 | 80.01 | 78.94 | 66.97 |
Diluted EPS Before Non-Recurring Items | -0.10 | -0.23 | -0.67 | -0.30 | -0.34 |
Diluted Net EPS (GAAP) | -0.10 | -0.77 | -0.78 | -0.93 | -0.35 |
Fiscal Year end for Innate Pharma SA Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |